Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
复制标题
DOI：
10.1200/jco.20.6.1467
复制
发表时间：
2002-03-15
影响因子：
45.3
通讯作者：
Allard, J
中科院分区：
文献类型：
--
作者：
Lipton, A;Ali, SM;Allard, J
目的：探讨血清HER-2/neu升高对激素治疗反应的影响。患者和方法：719例雌激素受体阳性(ER+)、孕激素受体阳性或两者均阳性或ER状态不明的转移性乳腺癌患者随机分为3个独立临床试验组，接受甲地孕酮或芳香化酶抑制剂(法曲唑或来曲唑)的二线激素治疗。结果：219例(30%)患者血清HER-2/neu蛋白水平升高，以健康女性血清+2SD平均值(15 ng/mL)为上限。711名患者对治疗有反应。494例血清HER-2/neu升高患者内分泌治疗有效率(完全缓解+部分缓解+病情稳定)为45%，217例血清HER-2/neu升高患者为23%(P
Purpose: To determine the effect of elevation of serum HER-2/neu on response to hormone therapy.Patients and Methods: Seven hundred nineteen metastatic patients with estrogen receptor-positive (ER+), progesterone receptor-positive, or both or ER status unknown breast cancer were randomized in three independent clinical trials to receive second-line hormone therapy with either megestrol acetate or an aromatase inhibitor (fadrozole or letrozole). An automated enzyme-linked immunosorbent assay specific for the extracellular domain of the HER-2/neu (c-erbB-2) oncoprotein product was used to detect serum levels.Results: Two hundred nineteen patients (30%) had elevated serum HER-2/neu protein levels, using the mean + 2 SD (15 ng/mL) from the serum of healthy women as an upper limit. Response to treatment was available for 711 patients. The response rate (complete responses plus partial responses plus stable disease) to endocrine therapy was 45% in 494 patients with non-elevated and 23% in 217 patients with elevated serum HER-2/neu levels (P